Wikipedia

TACT833

TACT833
Clinical data
Other namesTACT-833
Drug classMonoamine transporter modulator; Serotonin 5-HT1B receptor modulator
ATC code
  • None

TACT833 is a monoamine transporter modulator and serotonin 5-HT1B receptor modulator which is under development for the treatment of alcohol use disorder, anorexia, and binge-eating disorder.[1][2][3][4] It is being developed by Tactogen.[1][2][3][4] As of the first quarter of 2025, the drug is in the preclinical research stage of development.[1][2][3] The exact chemical structure of TACT833 does not yet appear to have been disclosed,[4] but it may be a benzofuran like 5-MAPB, 6-MAPB, BK-5-MAPB, or BK-6-MAPB.[5]

See also

[edit]

References

[edit]
  1. ^ a b c "Delving into the Latest Updates on TACT411/833 with Synapse". Synapse. 14 June 2025. Retrieved 25 November 2025.
  2. ^ a b c Haichin M (2024). "Psychedelics Drug Development Tracker". Psychedelic Alpha. Retrieved 29 January 2025.
  3. ^ a b c "Tactogen Inc – Pipeline". Tactogen Inc. Retrieved 29 January 2025. OUR PIPELINE: [...] COMPOUND: TACT411/833*. TARGETS: 5-HT1B & MATs. INDICATION: Alcohol Use Disorder. Prevalence: 13.9%. STATUS: Preclinical. COMPOUND: TACT411/833*. TARGETS: 5-HT1B & MATs. INDICATION: Anorexia / Binge Eating Disorder. Prevalence: 3.6%. STATUS: Preclinical. [...] *We will make a final decision among our lead candidates after completing IND-enabling studies. Alternate lead candidates include TACT 523.
  4. ^ a b c Matthew Baggott, Tactogen (14 November 2025). Progress in Novel Entactogens as Therapeutics. 5th Annual Conference on Psychedelics and Psychedelic Medicine, Virtual, November 14-15, 2025. Massachusetts General Hospital.
  5. ^ US 20230150963, Matthew Baggott, "Advantageous benzofuran compositions for mental disorders or enhancement", published 2023 May 18, assigned to Tactogen 
Stub icon

This psychoactive drug-related article is a stub. You can help Wikipedia by expanding it.